Medical Condition News

RSS

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Study investigates knowledge about khat among medical students in Yemen

A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.

8 Mar 2012

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

The agenda for the Optimizing PCI Outcomes: A Vision for 2012 symposium is now available at: http://www.pcioutcomes.com/conference/agenda.html. This evening symposium will feature the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease, including the latest clinical data on current and second-generation drug-eluting stent device-based therapies.

8 Mar 2012

First ever analysis of genetic variation between different regions of same tumour

Taking a sample from just one part of a tumour may not give a full picture of its 'genetic landscape', according to a landmark study published in the New England Journal of Medicine.

8 Mar 2012

Ugandan government draws up response plan to combat 'nodding disease'

The Ugandan government is creating a "wide-ranging response plan" to "nodding disease, a mysterious ailment characterized by seizures, nodding of the head, mental retardation and stunting, which affects thousands of children in northern Uganda," IRIN reports.

8 Mar 2012

MRF clinical trial to examine antigen-specific MS therapy

The Myelin Repair Foundation (MRF) announced today that its research might soon lead into a clinical proof-of-concept trial at the Department of Neuroimmunology and Multiple Sclerosis Research (nims), University Hospital Zürich, Switzerland, and the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims) in Hamburg, Germany.

8 Mar 2012

CB2 receptor involved in regulating impulsive behaviour

A new study lead by the Neuroscience Institute of Alicante reveals how manipulating the endocannabinoid system can modulate high levels of impulsivity. This is the main problem in psychiatric illnesses such a schizophrenia, bipolar disorder and substance abuse.

8 Mar 2012

Public reporting improves diabetes care in Wisconsin clinics

In one of the first studies of the impact of publicly reporting quality measures on outpatient care, a research team has found that clinics made improvements in diabetes care when they began publicly reporting how they were treating patients with the chronic disease.

8 Mar 2012

Scientists identify 2,000 important genes linked to singing

Can the song of a small bird provide valuable insights into human stuttering and speech-related disorders and conditions, including autism and stroke? New research by UCLA life scientists and colleagues provides reason for optimism.

8 Mar 2012

Daylight-saving time may increase risk of heart attack

Daylight-saving time this year begins March 11, and while we all might look forward to another hour of sunshine a University of Alabama at Birmingham expert says the time change is not necessarily good for your health.

8 Mar 2012

Berry fruits help the brain stay healthy in several ways

Strong scientific evidence exists that eating blueberries, blackberries, strawberries and other berry fruits has beneficial effects on the brain and may help prevent age-related memory loss and other changes, scientists report.

8 Mar 2012

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams (mg) via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

8 Mar 2012